353TiP Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01 [PDF]
, 2023 Snehal Patel +4 more
openalex +1 more source
Long‐Term Follow‐Up of Chemotherapy‐Associated Biological Aging in Women With Early Breast Cancer
Aging and Cancer, EarlyView.Women threated with adjuvant chemotherapy for early breast cancer have sustained long‐term increase in p16INK4a,, a robust marker of cell senescence, suggesting a chemotherapy‐associated age acceleration. p16INK4a as well as other biomarkers may identify patients at greatest risk for senescence‐related diseases of aging.
Hyman B. Muss +12 more
wiley +1 more source
Thoracic CancerBackground Circulating tumor DNA (ctDNA) has emerged as a potential novel biomarker to predict molecular residual disease (MRD) in lung cancer after definitive treatment.
Xiaoru Tian +13 more
doaj +1 more source
Commentary: Adjuvant therapy in resected T1 2N0 non–small cell lung cancer: Surgeons should lead [PDF]
, 2021 Neel P. Chudgar, Brendon M. Stiles
openalex +1 more source
Exceptional and Durable Responses to TDM-1 After Trastuzumab Failure for Breast Cancer Skin Metastases: Potential Implications of an Immunological Sanctuary [PDF]
, 2018 Breast Cancer (BC) skin metastases represent a challenging clinical scenario. Although they usually arise when other distant metastases are already present, they may also represent a form of locoregional recurrence (LRR). Systemic therapy in this setting
Dieci, Maria V +8 more
core +1 more source
Aging and Cancer, EarlyView.This systematic review synthesizes prognostic models for survival and recurrence in resected non‐small cell lung cancer. While many models demonstrate moderate to good discrimination, few are externally validated and reporting quality is variable, limiting clinical applicability and highlighting the need for robust, transparent model development ...
Evangeline Samuel +4 more
wiley +1 more source
Erratum to: Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer [PDF]
, 2011 Philip Bao +9 more
openalex +1 more source
Evaluation of a tumor microenvironment-based prognostic score in primary operable colorectal cancer [PDF]
, 2015 Purpose: The tumor microenvironment is recognized as an important determinant of progression and outcome in colorectal cancer. The aim of the present study was to evaluate a novel tumor microenvironment–based prognostic score, based on histopathologic ...
Edwards, Joanne +6 more
core +1 more source
Tracking Motor Progression and Device‐Aided Therapy Eligibility in Parkinson's Disease
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To characterise the progression of motor symptoms and identify eligibility for device‐aided therapies in Parkinson's disease, using both the 5‐2‐1 criteria and a refined clinical definition, while examining differences across genetic subgroups.
David Ledingham +7 more
wiley +1 more source